AWA
NKTR icon

Arete Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Arete Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-733
Closed -$35K – 685
2022
Q3 		$35K Buy
+733
New +$43.6K ﹤0.01% 563
2022
Q2 		– Sell
-733
Closed -$59K – 525
2022
Q1 		$59K Buy
+733
New +$108K ﹤0.01% 497

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Arete Wealth Advisors's NKTR Position: Q4 2022 in Review

Arete Wealth Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 733 shares — an estimated $35K sold.

Arete Wealth Advisors first reported a position in NKTR in Q1 2022 and held it in 2 quarters. The position peaked at $59K in Q1 2022. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

  • Arete Wealth Advisors reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Arete Wealth Advisors sold 733 Nektar Therapeutics shares in Q4 2022, an estimated $35K.
  • Arete Wealth Advisors first reported a position in Nektar Therapeutics in Q1 2022 and held it in 2 quarters.
  • Arete Wealth Advisors's Nektar Therapeutics position peaked at $59K in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Arete Wealth Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.